68444-12-2

Basic information

• Product Name: sodium alpha-hydroxy-m-nitrotoluene-alpha-sulphonate
• Synonyms: sodium alpha-hydroxy-m-nitrotoluene-alpha-sulphonate;(3-Nitrophenyl)hydroxymethanesulfonic acid sodium salt;α-Hydroxy-3-nitrobenzenemethanesulfonic acid sodium salt
• CAS NO: 68444-12-2
• Molecular Formula: C₇H₆NO₆S*Na
• Molecular Weight: 255.18041
• EINECS: 270-584-1
• Mol File: 68444-12-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: sodium alpha-hydroxy-m-nitrotoluene-alpha-sulphonate(CAS DataBase Reference)
• NIST Chemistry Reference: sodium alpha-hydroxy-m-nitrotoluene-alpha-sulphonate(68444-12-2)
• EPA Substance Registry System: sodium alpha-hydroxy-m-nitrotoluene-alpha-sulphonate(68444-12-2)

Safety Data

• Hazardous Substances Data: 68444-12-2(Hazardous Substances Data)

Upstream product

• 99-61-6 3-nitro-benzaldehyde 

Downstream Products

• 77219-08-0 2-(3-nitrophenyl)-3,3,4-tricyano-5-amino-2,3-dihydrofuran 
• 62673-14-7 trimethyl(3-nitrobenzyloxy)silane 
• 15601-45-3 4-(3'-nitrobenzylidene)-2-phenyl-4-oxazolone 
• 1147718-28-2 5-chloro-1-cyclopentyl-6-ethoxy-2-(3-nitrophenyl)-1H-benzimidazole 
• 1147718-62-4 2-(3-nitrophenyl)-5-chloro-1-cyclopentyl-1H-benzimidazole 
• 15456-62-9 2-(3-nitrophenyl)-1H-benzimidazole 
• 123371-44-8 nifetepimine 
• 555-68-0 (E)-3-Nitrocinnamic acid 
• 99-61-6 3-nitro-benzaldehyde 

Relevant articles and documents

Benzimidazole derivatives: Synthesis, leishmanicidal effectiveness, and molecular docking studies

Leishmanolysin GP63 is a zinc metalloprotease, expressed at the surface of Leishmania promastigotes. Studies on this protein are hindered as only a limited number of effective non-toxic inhibitors of this drug target are known. Present study describes the identification of a variety of 2-aryl- and 5-nitro-2-arylbenzimidazoles as new GP63 inhibitors. All the compounds were tested for in vitro activity against the promastigote form of Leishmania major and showed very good activity. 2-(Thiophen-2-yl)-1H-benzimidazole (19) and 2-(1H-indol-3-yl)-5-nitro-1H-benzimidazole (34) with IC50 value of 0.62 μg/mL were identified as lead of this library. Molecular docking studies were performed on binding site of GP63 to study the binding mode of compounds. The results of both in vitro and in silico studies clearly indicated that benzimidazoles may serve as new drug candidates in the combat against leishmaniasis.

Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA

The novel benzimidazole derivatives (3, 5, 8, 9, 12-14, 18-41) were prepared in this paper and the antimicrobial activities of these compounds against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA, standard and clinical isolates), Bacillus subtilis, Escherichia coli and Candida albicans were evaluated. Compounds 24-26 which have no substitution of N-1 position displayed better antibacterial activities than those of standards (ciprofloxacin, ampicillin and sultamicillin) against both the drug-resistant bacteria (MRSA, standard and clinical isolates). These derivatives (24-26), 2,5,6-trihalogenobenzimidazole analogues (8, 12), 5,6-dichloro-2-amino derivative (13), and 5-chloro-2-(4-benzyloxyphenyl)benzimidazole (35) exhibited the most potent antibacterial activity with MIC 3.12 μg/ml against S. aureus.